Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2549-2556

  Michailowsky, Vladimir ^a,b   Murta, Silvane M F ^a,b   Carvalho Oliveira, Leonardo ^b   Pereira, Maria E S ^b   Ferreira, Ludmila R P ^a,b   Brener, Zigman ^b   Romanha, Alvaro J ^b   Gazzinelli, Ricardo T ^a,b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; GAMMA INTERFERON; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CHAGAS DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; MALE; MORTALITY; MOUSE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STRAIN DIFFERENCE; SURVIVAL; TRYPANOSOMA CRUZI;

EID: 0031714971     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2549     Document Type: Article

References (52)

1. Adams, L. B., J. B. Hibbs, Jr., R. R. Taintor, and J. L. Krahenbuhl. 1990. Microbiostatic effect of murine-activated macrophages for Toxoplasma gondii. Role for synthesis of inorganic nitrogen oxides from L-arginine. J. Immunol. 144:2725-2729.
2. Aliberti, J. C. S., M. A. G. Cardoso, G. A. Martins, R. T. Gazzinelli, L. Q. Vieira, and J. S. Silva. 1996. IL-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect. Immun. 64:1961-1967.
3. Allen, J., and B. Ullman. 1994. Molecular characterization and overexpression of hypoxantine guanine phosphoribosyl transferase gene from Trypanosoma crui. Mol. Biochem. Parasitol. 65:233-245.
4. Andrade, A. L. S. S., F. Zicker, R. M. Oliveira, S. Almeida, A. Luquetti, L. R. Travassos, I. C. Almeida, S. S. Andrade, J. G. Andrade, and C. M. T. Martelli. 1996. Randomized trial of efficacy of henznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348:1407-1413.
5. Andrade, S. G., L. A. R. Freitas, S. Peyrol, A. R. Pimentel, and M. Sadigursky. 1991. Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice. Bull. W. H. O. 69:191-197.
6. Andrade, S. G., A. C. Filho, A. J. M. de Souza, E. S. de Lima, and Z. Andrade. 1997. Influence of treatment with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi. Int. J. Exp. Pathol. 78: 391-399.
7. Araújo, M. S. S., J. Molina, M. E. S. Pereira, and Z. Brener. 1996. Combination of drugs in the treatment of experimental Trypanosoma cruzi infection. Mem. Inst. Oswaldo Cruz 91:315.
8. Biron, A. C., and R. T. Gazzinelli. 1995. Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Curr. Opin. Immunol. 7:485-493.
9. Brener, Z. 1962. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev. Inst. Med. Trop. 4:389-396.
10. Brener, Z. 1992. Chagas disease - clinical features. Chagas disease (American trypanosomiasis): its impact on transfusion and clinical medicine. Int. Soc. Blood Transfusion Cap. 6:81-101.
11. Brener, Z., and E. Chiari. 1963. Variacões morfológicas observadas em diferentes amostras de Trypanosoma cruzi. Rev. Inst. Med. Trop. 5:220-224.
12. Camargo, E. P. 1964. Growth and differentiation in Trypanosoma cruzi. Origin of metacyclic trypanosomas in liquid media. Rev. Inst. Med. Trop. 6:93-100.
13. Camargo, M. M., I. C. Almeida, M. E. S. Pereira, M. A. J. Ferguson, L. R. Travassos, and R. T. Gazzinelli. 1997. GPI-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes initiate the synthesis of pro-inflammatory cytokines by macrophages. J. Immunol. 158:5890-5901.
14. Camargo, M. M., A. C. Andrade, I. C. Almeida, L. R. Travassos, and R. T. Gazzinelli. 1997. Glycoconjugates isolated from Trypanosoma cruzi but not from Leishmania sp. parasite membranes trigger nitric oxide synthesis as well as microbicidal activity by IFN-γ-primed macrophages. J. Immunol. 159: 6131-6139.
15. Cardillo, F., J. C. Voltarelli, S. G. Reed, and J. S. Silva. 1996. Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin-10: the role of NK cells. Infect. Immun. 64:128-134.
16. Clemons, K. V., E. Brummer, and D. A. Stevens. 1994. Cytokine treatment of central nervous system infection: efficacy of IL-12 alone and synergy with conventional antifungal therapy in experimental cryptococcoses. Antimicrob. Agents Chemother. 38:460-464.
17. Dias, J. P. C. 1987. Control of Chagas' disease in Brazil. Parasitol. Today 3:336-341.
18. Diaz De Toranzo, E. G., J. Castro, and J. J. Frankle De Cazzulo. 1988. Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA. proteins and lipids from Trypanosoma cruzi. Experientia 44: 880-881.
19. Docampo, R., and S. N. J. Moreno. 1985. Biochemical toxicology of antiparasitic compounds used in the chemotherapy and chemoprophylaxis of American trypanosomiasis (Chagas' disease). Rev. Biochem. Toxicol. 7:159-204.
20. Federici, E. E., W. H. Albemann, and F. A. Neva. 1964. Chronic and progressive myocarditis and myositis in C3H mice infected with Trypanosoma cruzi. Am. J. Trop. Med. Hyg. 13:272-280.
21. Filardi, L. S., and Z. Brener. 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans. R. Soc. Trop. Med. Hyg. 81:755-759.
22. Galvão, L. M. C., M. B. Nunes, J. R. Cançado, Z. Brener, and A. U. Kretteli. 1992. Lytic antibody titre as a means of assessing cure after treatment of Chagas' disease: a 10 years follow-up study. Trans. R. Soc. Trop. Med. Hyg. 86:1-4.
23. Gazzinelli, R. T., I. P. Oswald, S. Hieny, S. James, and A. Sher. 1992. The microbicidal activity of interferon-γ treated macrophages against Trypanooma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-β. Eur. J. Immunol. 22:2501-2506.
24. Gazzinelli, R. T., I. P. Oswald, S. James, and A. Sher. 1992. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ activated macrophages. J. Immunol. 148:1792-1796.
25. Gazzinelli, R. T., M. Wysocka, S. Hayashi, E. Y. Denkers, S. Hieny, P. Caspar, G. Trinchieri, and A. Sher. 1994. Parasite induced IL-12 stimulates early IFNγ synthesis and resistance during infection with Toxoplasma gondii. J. Immunol. 153:2533-2543.
26. Hunter, C. A., T. Slifer, and F. Araujo. 1996. Interleukin-12-mediated resistance to Trypanosoma cruzi is dependent on tumor necrosis factor alpha and gamma interferon. Infect. Immun. 64:2381-2386.
27. Krettli, A. U., J. R. Cançado, and Z. Brener. 1984. Criterion of cure human Chagas' disease after specific chemotherapy: recent advances. Mem. Inst. Oswaldo Cruz 79:157-164.
28. Minoprio, P., H. Eisen, M. Joskowicz, P. Pereira, and A. Coutinho. 1987. Suppression of polyclonal antibody production in murine Trypanosoma cruzi infected mice by treatment with anti-L3T4 antibodies. J. Immunol. 139:545-550.
29. Nabors, G. S., L. C. C. Afonso, J. P. Farrell, and P. Scott. 1995. A switch from a Th2 to Th1 type response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and pentostam. Proc. Natl. Acad. Sci. USA 92:3142-3146.
30. Nathan, C., N. Nogueira, C. Juangbhanich, J. Ellis, and Z. Cohn. 1979. Activation of macrophages: in vivo and in vitro correlation between hydrogen peroxide release and killing of Trypanosoma cruzi. J. Exp. Med. 149:1056.
31. Nathan, C. F., and J. B. Hibbs. 1991. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3:65.
32. Orange, C. A., S. F. Wolf, and C. A. Biron. 1994. Effects of IL-12 on the response and susceptibility to experimental viral infections. J. Immunol. 152:1253-1264.
33. Ortiz-Ortiz, L., T. Ortega, R. Capin, and T. Martinez. 1976. Enhanced mononuclear phagocytic activity during Trypanosoma cruzi infection in mice. Int. Arch. Allergy Appl. Immunol. 50:232-242.
34. Reed, S. G. 1988. In vivo administration of recombinant IFNγ induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J. Immunol. 140:4342-4347.
35. Santos, F. R., S. D. J. Pena, and J. T. Epplen. 1993. Genetic and population study of a Y-linked tetranucleotide repeat DNA polymorphism. Hum. Genet. 90:655-656.
36. Schlemper, B. R., Jr., C. M. Avila, J. R. Coura, and Z. Brener. 1983. Course of infection and histopathological lesions in mice infected with seventeen Trypanosoma cruzi strains isolated from chronic patients. Rev. Soc. Bras. Med. Trop. 16:23-30.
37. Silva, J. S., P. J. Morrissey, K. H. Grabstein, K. M. Mohler, D. Anderson, and S. G. Reed. 1992. Interleukin-10 and interferon-γ regulation of experimental Trypanosoma cruzi infection. J. Exp. Med. 175:169-174.
38. Silva, L. H. P., and V. Nussenzweig. 1953. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para camundongo branco. Folia Clin. Biol. 20:191-207.
39. Sypeck, T., C. L. Chung, S. E. H. Mayor, J. M. Subramanyam, S. J. Goldman, D. S. Sieburth, and S. F. Wolf. 1993. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective type 1 immune response. J. Exp. Med. 177:1797-1802.
40. + T cells increases susceptibility and reverses vaccine-induced immunity in mice infected with Trypanosoma cruzi. J. Immunol. 144:717-724.
41. Tarleton, R. L., B. H. Koller, A. Latour, and M. Postan. 1992. Susceptibility of β2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 356:338-340.
42. Texeira, A. R., E. R. Arganaraz, L. H. Freitas, Jr., Z. G. Lacava, J. M. Santana, and H. Luna. 1994. Possible integration of Trypanosoma cruzi kDNA minicircles into the host cell genome by infection. Mutat. Res. 305: 197-209.
43. Toledo, M. J. O., G. B. N. Machado, M. E. S. Pereira, and Z. Brener. 1991. Results of treatment in mice immunosuppressed inoculated with different Trypanosoma cruzi strains. Mem. Inst. Oswaldo Cruz 86:237.
44. Torrico, F., H. Heremans, M. T. Rivera, E. Van Mark, A. Billiau, and Y. Carlier. 1991. Endogenous IFNγ is required for resistance to acute Trypanosoma cruzi infection in mice. J. Immunol. 146:3626-3632.
45. Trinchieri, G. 1995. Interleukin 12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251-276.
46. Tripp, C. S., M. K. Gately, J. Hakini, P. Ling, and E. R. Unanue. 1994. Neutralization of IL-12 decreases resistance to Listeria in SCID and CB-17 mice, reversal by IFNγ. J. Immunol. 152:1883-1887.
47. Urbina, J. A., G. Payares, J. Molina, C. Sanoja, A. Liendo, K. Lazarde, M. Piras, R. Piras, N. Peres, P. Wincker, and J. Ryley. 1996. Cure of a short- and long-term experimental Chagas' disease using DO870. Science 273:969-971.
48. Vespa, G. N. R., F. Q. Cunha, and J. S. Silva. 1994. Nitric oxide is involved in the control of Trypanosoma cruzi induced parasitemia and directly kills parasite in vitro. Infect. Immun. 62:5177-5182.
49. World Health Organization. 1990. Chagas disease-frequency and geographical distribution. Weekly Epidemiol. Rec. W. H. O. 65:125-135, 257-261.
50. World Health Organization. 1995. Chagas disease, p. 125-135. In Tropical disease research. Twelfth Programme of UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). World Health Organization, Geneva, Switzerland.
51. Zhou, P., M. C. Sieve, J. Bennett, K. J. Kwon-Chung, R. P. Tewari, R. T. Gazzinelli, A. Sher, and R. A. Seder. 1995. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction IFNγ. J. Immunol. 155:785-795.
52. Zhou, P., M. C. Sieve, R. P. Tewari, and R. A. Seder. 1997. Interleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum. Infect. Immun. 65:1-7.